CEL SCI CORP

CVM is the ticker symbol for CEL SCI CORP, a publicly traded US company.

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Key metrics include a return on equity of -79.5%, a debt-to-equity ratio of 1.58.

The company reports trailing twelve-month revenue of $51,822 and net loss of $5.47M.

FINOTAUR aggregates real-time and fundamental data on CVM to help traders and investors make informed decisions. Track CVM in your trading journal alongside other positions for a unified view of your portfolio.